Lupin Ltd, Mumbai, a leading global player in anti-TB, Cephalosporins (anti-infectives) and cardiovascular drugs (prils and statins), has received Euro 20 million from Laboratoires Servier of France for the sale of certain patent applications and other related Intellectual Property for Perindopril for multiple countries.

"The income from this sale significantly boosts our performance for the previous quarter. It obviously goes a long way to demonstrate our research and IP capabilities," said Dr Kamal Sharma, managing director, Lupin Ltd.

For the nine-month period ended December 2006, the company's revenues and profit after tax were Rs 14,985 million (US$ 335 million) and Rs 1,650 million (US$ 37 million) respectively. Lupin has a programme for developing New Chemical Entities. The company has a state-of-the-art R&D centre in Pune, Maharashtra.